company background image
NGEN

NervGen Pharma TSXV:NGEN Stock Report

Last Price

CA$1.70

Market Cap

CA$99.8m

7D

-12.8%

1Y

-19.8%

Updated

24 Sep, 2022

Data

Company Financials +
NGEN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

NGEN Stock Overview

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage.

NervGen Pharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NervGen Pharma
Historical stock prices
Current Share PriceCA$1.70
52 Week HighCA$3.33
52 Week LowCA$1.52
Beta1.56
1 Month Change-14.57%
3 Month Change-9.57%
1 Year Change-19.81%
3 Year Change27.82%
5 Year Changen/a
Change since IPO-2.30%

Recent News & Updates

Shareholder Returns

NGENCA PharmaceuticalsCA Market
7D-12.8%-10.6%-4.8%
1Y-19.8%-66.8%-7.2%

Return vs Industry: NGEN exceeded the Canadian Pharmaceuticals industry which returned -64.9% over the past year.

Return vs Market: NGEN underperformed the Canadian Market which returned -4.6% over the past year.

Price Volatility

Is NGEN's price volatile compared to industry and market?
NGEN volatility
NGEN Average Weekly Movement11.4%
Pharmaceuticals Industry Average Movement11.6%
Market Average Movement9.9%
10% most volatile stocks in CA Market18.4%
10% least volatile stocks in CA Market3.7%

Stable Share Price: NGEN is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: NGEN's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017n/aBill Radvakhttps://www.nervgen.com

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer’s disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage.

NervGen Pharma Fundamentals Summary

How do NervGen Pharma's earnings and revenue compare to its market cap?
NGEN fundamental statistics
Market CapCA$99.75m
Earnings (TTM)-CA$19.03m
Revenue (TTM)n/a

0.0x

P/S Ratio

-5.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NGEN income statement (TTM)
RevenueCA$0
Cost of RevenueCA$0
Gross ProfitCA$0
Other ExpensesCA$19.03m
Earnings-CA$19.03m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.32
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did NGEN perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is NGEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NGEN?

Other financial metrics that can be useful for relative valuation.

NGEN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-4.6x
PEG Ration/a

Price to Book Ratio vs Peers

How does NGEN's PB Ratio compare to its peers?

NGEN PB Ratio vs Peers
The above table shows the PB ratio for NGEN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average4.1x
ACRG.A.U Acreage Holdings
0.3x84.8%US$89.8m
LOVE Cannara Biotech
1.6xn/aCA$100.9m
INNO InnoCan Pharma
6.1xn/aCA$60.9m
RVV Revive Therapeutics
8.6xn/aCA$129.3m
NGEN NervGen Pharma
10.1xn/aCA$99.8m

Price-To-Book vs Peers: NGEN is expensive based on its Price-To-Book Ratio (10.1x) compared to the peer average (4.1x).


Price to Earnings Ratio vs Industry

How does NGEN's PE Ratio compare vs other companies in the CA Pharmaceuticals Industry?

Price-To-Book vs Industry: NGEN is expensive based on its Price-To-Book Ratio (10.1x) compared to the Canadian Pharmaceuticals industry average (0.9x)


Price to Book Ratio vs Fair Ratio

What is NGEN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NGEN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio10.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate NGEN's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of NGEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NGEN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NGEN's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Future Growth

How is NervGen Pharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


70.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if NGEN's forecast earnings growth is above the savings rate (1.6%).

Earnings vs Market: Insufficient data to determine if NGEN's earnings are forecast to grow faster than the Canadian market

High Growth Earnings: Insufficient data to determine if NGEN's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if NGEN's revenue is forecast to grow faster than the Canadian market.

High Growth Revenue: NGEN is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NGEN's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has NervGen Pharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-46.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: NGEN is currently unprofitable.

Growing Profit Margin: NGEN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NGEN is unprofitable, and losses have increased over the past 5 years at a rate of 46.2% per year.

Accelerating Growth: Unable to compare NGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NGEN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (39.8%).


Return on Equity

High ROE: NGEN has a negative Return on Equity (-192.7%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is NervGen Pharma's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: NGEN's short term assets (CA$12.2M) exceed its short term liabilities (CA$2.9M).

Long Term Liabilities: NGEN's short term assets (CA$12.2M) exceed its long term liabilities (CA$241.0K).


Debt to Equity History and Analysis

Debt Level: NGEN is debt free.

Reducing Debt: NGEN has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NGEN has sufficient cash runway for 11 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: NGEN is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies

Dividend

What is NervGen Pharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate NGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NGEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NGEN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NGEN has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average board tenure


CEO

Bill Radvak (59 yo)

no data

Tenure

CA$97,500

Compensation

Mr. William Joseph Radvak, also known as Bill, BASc, serves as Interim Chief Executive Officer at NervGen Pharma Corp. since September 23, 2022. He served as Chief Executive Officer at Regency Gold Corp. s...


CEO Compensation Analysis

Compensation vs Market: Paul's total compensation ($USD345.91K) is above average for companies of similar size in the Canadian market ($USD177.75K).

Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.


Board Members

Experienced Board: NGEN's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: NGEN insiders have only sold shares in the past 3 months.


Recent Insider Transactions

TSXV:NGEN Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
19 Aug 22SellCA$11,275William RadvakIndividual5,500CA$2.05
29 Nov 21BuyCA$208,000William RadvakIndividual80,000CA$2.60

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 44.3%.


Top Shareholders

Top 10 shareholders own 25.59% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
17.04%
PFP Biosciences Holdings
10,000,000CA$17.0m0%no data
4.18%
Harold Punnett
2,450,000CA$4.2m4.26%no data
2.2%
William Radvak
1,289,500CA$2.2m-0.42%no data
1.06%
Paul Brennan
619,354CA$1.1m8.78%no data
0.77%
Brian Bayley
450,000CA$765.0k28.57%no data
0.19%
William Adams
111,750CA$190.0k75.29%no data
0.085%
Glenn Ives
50,000CA$85.0k0%no data
0.051%
CapFinancial Partners, LLC, Asset Management Arm
30,000CA$51.0k0%no data
0.017%
Adam Rogers
10,000CA$17.0k0%no data
0.0058%
FNY Investment Advisers, LLC
3,400CA$5.8k0%no data

Company Information

NervGen Pharma Corp.'s employee growth, exchange listings and data sources


Key Information

  • Name: NervGen Pharma Corp.
  • Ticker: NGEN
  • Exchange: TSXV
  • Founded: 2017
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CA$99.754m
  • Shares outstanding: 58.68m
  • Website: https://www.nervgen.com

Number of Employees


Location

  • NervGen Pharma Corp.
  • 2955 Virtual Way
  • Suite 480
  • Vancouver
  • British Columbia
  • V5M 4X6
  • Canada


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NGENTSXV (TSX Venture Exchange)YesCommon SharesCACADMar 2019
NGEN.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDMar 2019
9UADB (Deutsche Boerse AG)YesCommon SharesDEEURMar 2019

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/24 00:00
End of Day Share Price2022/09/23 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.